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z.2012.12Abstract 2-Nitropropane (2-NP) is suggested to be a human carcinogen, a genotoxicant and
hepatocarcinogen in rodents. The present study was designed to evaluate the role of melatonin
(Mel) as an anticancerous agent in hepatocellular carcinoma (HCC) induced by 2-NP. Forty eight
male Swiss albino mice were divided into 5 groups. Group I, II and III served as controls. Group IV
was injected IP with 2-NP every other day for 14 weeks. Group V was injected IP with melatonin
30 min prior to 2-NP injection. Mice were sacriﬁced after 4, 8 and 14 weeks. Histopathological
results showed poorly differentiated HCC; pleomorphic atypical hepatocytes after 8 weeks of
receiving 2-NP. Proliferating streaks and cords of malignant hepatocytes were prominent after
14 weeks of 2-NP injection. (Mel + 2-NP) treatment revealed histological features more or less sim-
ilar to normal control with dilated sinusoids, evidence of apoptosis, eosinophilic cytoplasm, few
large necrotic cells, microsteatosis and well deﬁned Kupffer cells. Histochemically, group IV
showed continuous decrease in catalase activity and very weak activity was reached after 14 weeks.
In group V, marked and moderate catalase activity was observed after 4 and 8 weeks, respectively as
well as marked diffused reaction after 14 weeks. Immunohistochemically, PCNA and VEGF
expressions were signiﬁcantly increased in group IV and this increment was time dependant.
Decreased numbers of PCNA and VEGF expressions in group V were seen as compared with their
counterparts. It was concluded that 2-NP was a hepatocellular carcinogen in mice and melatonin
exerted its anticancerous role through its antiproliferative and antiangiogenic effects.
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.004Introduction
Hepatocellular carcinoma (HCC) is a primary liver cancer
that arises from hepatocytes, the major cell type in the liver.
It is the most common primary hepatic tumor and the ﬁfth
most common cancer worldwide, in addition to being the
third most common cause of cancer mortality which affectedhe Egyptian German Society for Zoology.
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year (Motola-Kuba et al., 2006 and El-Serag and Rudolph,
2007).
Chemical carcinogens played an important role in the eti-
ology of HCCs (Zhang, 2010). Many recognized human car-
cinogens were occupational carcinogens (Siemiatycki et al.,
2004). Nitroalkanes were used widely in the chemical indus-
try for synthesizing common reagents, they were considered
to be toxic and carcinogenic (Mijatovic, 2008). One of these
nitroalkanes was 2-nitropropane (2-NP). It was widely used
as an industrial solvent in many industries (Sakano et al.,
2001). The liver was thought to be the target organ of 2-
NP toxicity which caused cell proliferation (El-Sokkary,
2002). It was hepatocarcinogenic in rats (Nakayama et al.,
2006; Mijatovic, 2008) and an oxidative stress inducing agent
in mice (Cabelof et al., 2002). The liver damage induced by 2-
NP was associated with oxidative damage and lipid peroxida-
tion (Borges et al., 2006). 2-NP induced DNA damage in the
liver tissue of mice (Unnikrishnan et al., 2009) by radicals
generated via hydrogen peroxide species (Sakano et al.,
2001).
Catalase is an antioxidant enzyme found in peroxisome,
plays a signiﬁcant role in protection against oxidative stress
by the decomposition of hydrogen peroxide (H2O2) (Marti´n-
Renedo et al., 2008; Ekanayake et al., 2008). This reaction
was important in the liver and kidney cells, where the peroxi-
somes detoxiﬁed different toxic substances entering the blood
(Alberts et al., 2002).
The vascular endothelial growth factors (VEGFs) are a
family of proteins which have a pivotal role in regulating tu-
mor angiogenesis (Shibuya and Claesson-Welsh, 2006). VEGF
is a potent cytokine that binds to speciﬁc receptors on the
endothelial cells lining blood vessels, triggering the signaling
cascade which led to the formation of new capillaries (angio-
genesis) (Stefanini et al., 2009). Vascular endothelial growth
factor (VEGF) and ﬁbroblast growth factor (FGF) are two
of the major factors among many factors involved in angiogen-
esis (Gjini, 2005).
Proliferating cell nuclear antigen (PCNA), a cell cycle mar-
ker protein, functions as a sliding clamp during DNA replica-
tion (Bowman et al., 2004 and Freudenthal et al., 2008).
PCNA presented in mammalian cells as a double homotrimeric
protein (Freudenthal et al., 2008). PCNA is involved in pro-
tein–protein interactions (Maga and Hubscher, 2003) and in
the DNA damage tolerance pathway known as post-replica-
tion repair (Lehmann and Fuchs, 2006).
Melatonin (N-acetyl-5-methoxytryptamine) is the main
secretory product of the pineal gland in mammals (Tan
et al., 2007), and is also produced in many organs and tissues
such as the retina, the gastrointestinal tract, skin, bone
marrow and 1ymphocytes (Pandi-Perumal et al., 2006).
Melatonin is a powerful scavenger of reactive oxygen species
(ROS), as well as being a stimulator of the antioxidant
enzymes: superoxide dismutase, glutathione peroxidase, and
catalases, that led to a decrease in DNA damage (Blask
et al., 2002).
The present study was designed to evaluate the role of
2-nitropropane (2-NP) in HCC induction in mice and the role
of melatonin as an anti-cancerous agent through the following
parameters: histopathological, histochemical and immunohis-
tochemical studies.Materials and methods
This study was carried out in accordance with the protocol of
Laboratory Animal Unit of Medical Research Institute, Alex-
andria University concerning guiding principles for biomedical
research involving animals.
The present study was carried out on forty eight male Swiss
albino mice, three month old and weighing 30 ± 10 g. They
were obtained from the Laboratory Animal Unit, Medical Re-
search Institute, Alexandria University. They were kept under
the same laboratory conditions of 20–25 C and 12 h light–
dark cycle and given free access to standard food and water.
They were then randomly divided into the following
groups:
Group I: Normal control group (6 mice).
Group II: Experimental control group (6 mice) was injected
IP with 1 ml of 10 mg melatonin (Amoun Co. Egypt)/kg
BW every other day (Ravindra et al., 2006) at 2 pm for
14 weeks. Melatonin (Mel.) was dissolved in ethanol before
being diluted with saline making the ﬁnal concentration of
ethanol in melatonin <1% (El-Sokkary et al., 2007).
Group III: Solvent control group (6 mice) was injected IP
with 1 ml of olive oil every other day for 14 weeks.
Group IV: Experimental group (15 mice) was injected IP
with 1 ml of 200 mg 2-NP (Sigma–Aldrich Chemie Co.),
dissolved in olive oil, /kg body weight (Borges et al.,
2006) every other day for 14 weeks.
Group V: Experimental treated group (15 mice) was
injected IP with 1 ml of 10 mg melatonin/kg body weight
every other day 30 min prior to 2-NP injection for
14 weeks.
Two mice from each control group and 4 mice from each
treated group were sacriﬁced after 4, 8 and 14 weeks from
the beginning of the experiment. Liver was dissected out and
the right lobe was cut into 2–4 mm3 pieces which were either
ﬁxed in 10% neutral buffered formalin for 24 h or used as fro-
zen cryostat sections. Then the following studies were
performed:
Histopathological study
Formalin ﬁxed specimens were processed and prepared to get
blocks. Sections 3 lm thick were cut and stained with hema-
toxylin and eosin (H&E) for histopathological investigations
(Bancroft and Stevens, 2002).
Histochemical study
3,3-Diaminobenzidine (DAB) method was used for studying
catalase, 10 m-thick cryostat sections were ﬁxed in acetone at
4 C for 5 min, incubated in buffered DAB solution (Without
hydrogen peroxide) for 1 min at room temperature, and then
rinsed in distilled water. The sections were incubated in DAB
solution with hydrogen peroxide for 15 min, washed in 3
changes of distilled water. Reaction was intensiﬁed in 0.1 M
phosphate buffer (pH 7.2) for 5 min, washed in distilled water
for 5 min and counterstained with toluidine blue, then dried
and mounted with glycerin gel (Kiernan, 2001).The control
reaction was performed through omitting the speciﬁc substrate.
Figure 1 Parafﬁn section of mouse liver in control groups showing: (a) normal liver structure with sinusoids (›), binucleate cell (arrow
head), Kupffer cells (thick arrow) and central vein (CV) with endothelial cells (›). (b) Liver with well-deﬁned Kupffer cells (arrow head)
and few microsteatosis (›) 14 weeks post-Mel. injection. (c) Liver with diffused macrosteatosis (arrow head) and apoptotic nuclei (›)
14 weeks post-olive oil injection (H&E – bar = 50 lm).
208 A.A. Abdel-Mawla et al.Catalase enzyme activity was ranked in all the studied
groups according to the following: intense reaction
(++++), marked reaction (+++), moderate reaction
(++) weak reaction (+).
Immunohistochemical study
Five-lm-thick neutral buffered formalin ﬁxed sections were
deparafﬁnized in xylene, hydrated in a descending series of eth-
anol to phosphate-buffered saline (PBS; pH 7.5). Sections were
prepared to quantify proliferating cell nuclear antigen (PCNA)
and vascular endothelial growth factor (VEGF) protein
expression. In brief, the avidin–biotin complex immunoperox-
idase staining system was used. Primary antibodies used were:
monoclonal mouse anti-proliferating cell nuclear antigen
(PCNA; clone PC 10; Dako Corporation, Carpentaria CA,
Denmark) and monoclonal mouse anti-human vascular endo-
thelial growth factor (VEGF; clone VG1; Dako Corporation,
Carpentaria CA, Denmark). Tissue refreshment was per-
formed using 3% H2O2 for 30 min at 100 C and washed in
two changes of PBS (each 5 min). The primary antibodies were
then linked with biotinylated goat anti-mouse IgG antibody
(Dako, LASB Universal) for 35 min at room temperature,
washed in two changes of PBS (each 5 min), then the sections
were incubated with streptavidin-conjugated peroxidase for
35 min. After being washed in PBS, the reaction was colored
by exposing sections to 3,3-diaminobenzidine (DAB) solution
for 10 min, then washed in distilled water (2 changes) and
counterstained with 1% methy1 green stain. After washing in
tap water, the sections were dehydrated, cleared in xylene
and mounted with Canada balsam. Control reaction wascarried out by removing speciﬁc primary antibodies for both
PCNA and VEGF (Claudio et al., 2004).
Results
Histopathological results
Control normal liver sections stained with H&E showed anas-
tomosing plates of hepatocytes radiating from the centrilobu-
lar venule toward the periphery of the hepatic lobule.
Hepatocytes were tightly packed, pink staining with round vio-
let nuclei containing prominent nucleoli. The majority of hepa-
tocytes contained a single nuclei and some cells had more than
one nucleus .The hepatocytes came in contact with blood sinu-
soids or neighboring hepatocytes and Kupffer cells were asso-
ciated with sinusoidal lining cells (Fig. 1a). Liver sections after
receiving melatonin for 14 weeks revealed normal histological
structure with well deﬁned Kupffer cells but with few micros-
teatosis (Fig. 1b). Examination of liver sections after receiving
olive oil for 14 weeks showed diffused macrosteatosis and few
apoptotic nuclei (Fig. 1c).
Examination of liver sections of group IV after receiving 2-
NP for 4 weeks showed prominent apoptosis, central vein with
acute and chronic inﬂammatory cellular inﬁlteration, hepato-
cytes with microsteatosis, in addition to necrotic cells around
the central vein (Fig. 2a and b). By the 8 week of receiving
2-NP, a poorly differentiated HCC was illustrated by its fea-
tures of loss of cord pattern and hepatic architecture forming
nests of pleomorphic atypical hepatocytes (Fig. 3a) with cellu-
lar and nuclear variation in shape and size (Fig. 3b). By the
14 week, the liver had macroscopic hepatic multinodules seen
Figure 2 Parafﬁn section of mouse liver 4 weeks post-injection of 2-NP showing: (a) prominent apoptosis (›). (H&E – bar = 200 lm).
(b) More acute and chronic inﬂammation (›), increased steatosis (arrow head), and more necrosis (\) near the central vein (CV) (H&E –
bar = 50 lm).
Figure 3 Parafﬁn section of mouse liver 8 weeks post-injection of 2-NP showing: (a) poorly differentiated HCC with loss of cord pattern,
loss of hepatic architecture forming nests of pleomorphic severely atypical hepatocytes (›). (H&E – bar = 200 lm). (b) Anaplastic tumor
cells with cellular and nuclear variation in shape and size (›). Note the necrotic cells (arrow head) (H&E – bar = 50 lm).
Induction of hepatocellular carcinoma in mice and the role of melatonin 209by the naked eye (Fig. 4a) and appeared in sections to be on
top of necrosis (Fig. 4b) with the loss of hepatic architecture
and having proliferating streaks and cords of malignant hepa-
tocytes (Fig. 4c).Examined liver sections of group V after 4 weeks of mel-
atonin + 2NP (Mel + 2-NP) treatment, revealed evidence
of histological features more or less similar to the normal
control group with dilated sinusoids (Fig. 5). After 8 weeks
Figure 4 Mouse liver 14 weeks post-injection of 2-NP: (a) note visible macronodules on the anterior side (›). (b) Parafﬁn section of
mouse liver showing malignant hepatic multi-nodules (\) on top of necrosis (arrow head). (H&E – bar = 500 lm). (c) Parafﬁn section of
mouse liver showing loss of hepatic architecture, proliferating streaks and cords of hyperchromatic malignant hepatocytes (›) (H&E –
bar = 50 lm).
Figure 5 Parafﬁn section of mouse liver 4 weeks post-(Mel + 2-NP) treatment showing minimal inﬂammation (›), dilated sinusoids
(arrow head), central vein (CV) and Kupffer cells ( ). (H&E – bar = 50 lm).
210 A.A. Abdel-Mawla et al.of treatment, the hepatocytes showed pyknotic nuclei with
chromatin condensation and aggregation peripherally under
the nuclear membrane, in addition to intensely eosinophilic
cytoplasm, this reﬂected the property of apoptosis (Fig. 6).By the 14th week of treatment, few large necrotic cells and
microsteatosis were observed while atypical nuclei were still
seen. Interestingly well deﬁned Kupffer cells were seen
(Fig. 7).
Figure 6 Parafﬁn section of mouse liver 8 weeks post-treatment with (Mel + 2-NP) showing apoptotic cells ( ) with intensely
eosinophilic cytoplasm (\), shrinkage of nuclei (arrow head) and necrotic cells (N). Note nuclear chromatin condensation peripherally
under the nuclear membrane (›) and Kupffer cells ( ) (H&E – bar = 50 lm).
Figure 7 Parafﬁn section of mouse liver 14 weeks post-(Mel + 2-NP) treatment showing large necrotic cells (arrow head), microsteatosis
(›) and large atypical nuclei ( ). Note central vein (CV) and Kupffer cells ( ) (H&E – bar = 50 lm).
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Catalase enzyme
Localization of catalase enzyme was performed using the DAB
method on frozen liver sections. Catalase activity was observed
as dark brown granules distributed in the cytoplasm referring
to the organelle-peroxisomes. The nuclei were stained blue by
toluidine blue stain. In normal control sections, catalaseactivity was illustrated as a marked coarse granular reaction
distributed in the cytoplasm around the nuclei of hepatocytes,
endothelial and Kupffer cells (Fig. 8a). Liver sections after
receiving melatonin showed no considerable change as com-
pared with normal counterparts along all the periods where
the intensity was marked. However, there were some intense
coarse granular reactions in the cytoplasm of some hepatocytes
(Fig. 8b). Examination of the liver sections of the olive oil
Figure 8 Frozen section of control mouse livers: (a) normal liver showing marked coarse catalase granular reaction (›) in the cytoplasm
of all liver cells especially around the nuclei ( ). (b) 14 weeks post Mel-injection showing marked activity of catalase. Note some intense
coarse granular reaction in the cytoplasm of some cells (›) c): 14 weeks post-olive oil injection showing intense catalase granular reaction
(DAB method – bar = 50 lm).
Figure 9 Frozen section of mouse liver post-injection of 2-NP Showing: (a) marked activity of catalase after 4 weeks. (b) Moderate
catalase activity after 8 weeks. (c) Very weak activity of catalase (arrow head) after 14 weeks. Note the few cells with intense reaction ( )
(DAB method – bar = 50 lm).
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reaction in the cytoplasm of hepatocytes, endothelial and
Kupffer cells (Fig. 8c).Examined liver sections of group IV after 4 weeks of 2-NP
injection showed a marked activity of catalase distributed in
the cytoplasm around the nuclei (Fig. 9a). After 8 weeks of
Figure 10 Frozen section of mouse liver post-(Mel + 2-NP) injection showing: (a) marked granular reaction of catalase activity after
4 weeks. (b) Moderate activity of catalase after 8 weeks. (c) Marked catalase activity after14 weeks (DAB method – bar = 50 lm).
Figure 11 Normal control mouse liver section showing few PCNA positive hepatocytes nuclei (›) (Avidin–biotin complex system –
bar = 50 lm).
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activity as compared with normal counterparts (Fig. 9b). By
the 14th week, catalase activity was very weak, despite the
presence of few cells with intense activity (Fig. 9c).
Examined liver sections of group V after 4 weeks of
(Mel + 2-NP) treatment showed a marked activity of catalasedistributed in the cytoplasm of hepatocytes (Fig. 10a). Moder-
ate activity of catalase was observed in the cytoplasm after
8 weeks the same as in the normal control group (Fig. 10b).
At the interval of 14 weeks, the enzyme activity was increased
as a marked diffused reaction in the cytoplasm around the nu-
clei (Fig. 10c).
Fig. 12 Mouse liver section post 2-NP injection showing: (a) slight increase in the number of PCNA positive nuclei (›) after 4 weeks. (b)
More increase in the number of PCNA positive nuclei (›) after 8 weeks. (c) Mouse liver section 14 weeks post-injection of 2-NP showing
the most increase in the number of PCNA positive nuclei (›). (Avidin–biotin complex system – bar = 50 lm).
Graph 1 A bar graph showing the mean number of PCNA
positive cells in the ﬁve studied groups after 4, 8, and 14 weeks.
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Proliferating cell nuclear antigen (PCNA)
PCNA immunostaining reaction was conﬁned to the nuclei.
The reaction product was present in different patterns from
a faint to strong densely stained nuclear granular reaction ﬁll-
ing the whole nucleus. Only moderately to strongly stained nu-
clei were considered as positive. Sections for the control
reaction gave a negative PCNA stain.
In the normal control liver sections, there were a few num-
bers of PCNA positive nuclei (Fig. 11). Examination of liver
sections in group II after receiving melatonin and in group
III after olive oil injection along all the intervals showed few
numbers of PCNA positive nuclei the same as the normal
group .
Examination of liver sections of group IV after 4 weeks
post 2-NP injection showed a slight increase in the number
of hepatocytes with positive nuclei compared to the normal li-
ver (Fig. 12a). After 8 weeks of 2-NP injection, this increase in
the number of PCNA positive nuclei was more pronounced
(Fig. 12b). By the 14th week of 2-NP injection the most pre-
dicted number of PCNA positive nuclei with strong intensity
of immunostaining was seen (Fig. 12c).
After 4 weeks of (Mel + 2-NP) treatment in group V, the
liver sections showed a slight decrease in the expression of
PCNA positive nuclei as compared with their counterparts
of group IV (Fig. 13a). By the 8th and 14th week, there was
an obvious decrease in the number of PCNA positive nuclei
as compared with their counterparts of group IV (Fig. 13b
and c).
These overall changes in PCNA between different groups or
inside one group at different intervals are summarized and
illustrated in Table 1 and Graph 1.Table 1 indicates that the number of PCNA positive nuclei
after the 4 week was signiﬁcantly different (p 6 0.05) in group
II and group IV comparing with the normal control group.
There was no signiﬁcant difference (p> 0.05) between group
III, group IV and group I. The number of PCNA positive nu-
clei was signiﬁcantly (p 6 0.01) higher in group V than in
group II and group III. There was no signiﬁcant difference
(p 6 0.05) in PCNA positive nuclei between group IV and
group V. After 8 weeks, the number of PCNA positive nuclei
was signiﬁcantly higher (p 6 0.01) in group IV and signiﬁ-
cantly lower (p 6 0.05) in group V than in the normal control
Fig. 13 Mouse liver section post-(Mel + 2-NP) injection showing: (a) few PCNA positive nuclei (›) after 4 weeks. (b) A decrease in
PCNA positive nuclei (›) after 8 weeks. (c) Few PCNA positive nuclei (›) after 14 weeks. (Avidin–biotin complex system – bar = 50 lm).
Table 1 Comparison between the mean number of PCNA positive cells in the ﬁve studied groups after 4, 8, and 14 weeks.
Group Range Mean ± SD p Value
p1 p2 p3 p4
Group I 4 weeks 1.0–5.0 2.90 ± 1.20
8 weeks 1.0–5.0 2.90 ± 1.37
14 weeks 1.0–5.0 2.50 ± 1.27
Group II 4 weeks 0–3.0 1.70 ± 1.06 0.039*
8 weeks 0–4.0 1.90 ± 1.20 NS
14 weeks 1.0–4.0 2.30 ± 1.16 NS
Group III 4 weeks 0–4.0 1.80 ± 1.14 NS NS
8 weeks 0–5.0 1.90 ± 1.52 NS NS
14 weeks 0–5.0 2.30 ± 1.49 NS NS
Group IV 4 weeks 1.0–10.0 4.30 ± 3.30 NS NS NS
8 weeks 2.0–11.0 7.30 ± 2.79 0.002** 0.002** 0.002**
14 weeks 18.0–33.0 27.9 ± 4.43 <0.001*** <0.001*** <0.001***
Group V 4 weeks 2.0–6.0 4.50 ± 1.18 0.012* 0.002** 0.002** NS
8 weeks 1.0–3.0 1.70 ± 0.67 0.041* NS NS <0.001***
14 weeks 1.0–4.0 2.30 ± 0.95 NS NS NS <0.001***
p1: p Value for Mann Whitney test between group I and other groups.
p2: p Value for Mann Whitney test between group II with group III, IV and V.
p3: p Value for Mann Whitney test between group III with group IV and V.
p4: p Value for Mann Whitney test between group IV and V.
NS: not signiﬁcant at p> 0.05.
* Statistically signiﬁcant at p 6 0.05.
** Statistically signiﬁcant at p 6 0.01.
*** Statistically signiﬁcant at p 6 0.001.
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group II and group V while the signiﬁcance (p 6 0.001) was re-
ported between group IV and group V referring to the injuri-
ous effect of 2-NP and the protective effect of melatonin. At
the 14th week, the number of PCNA positive nuclei in group
IV was signiﬁcantly higher (p 6 0.001) than in all theother groups referring to a high peak of proliferation due to
2-NP.
Vascular endothelial growth factor (VEGF)
Angiogenesis was visualized by immunostaining of liver sec-
tions with VEGF. The immunoreaction of VEGF was indi-
Figure 15 Immunohistochemical staining of VEGF in mouse liver section post injection of 2NP (Avidin biotin complex system –
bar = 50 lm) showing: (a) slight increase in number of positive VEGF reaction in hepatocytes (arrow head) and positivity in the sinusoids
(›) after 4 weeks. (b) More increase in number of positive VEGF reaction in hepatocytes (arrow head) after 8 weeks. (c) Noticeable
increase in number of positive VEGF reaction (›) after 14 weeks.
Fig. 14 Mouse liver section after 14 weeks post Mel injection showing few VEGF positive hepatocytes (›), sinusoidal lining cells and
endothelial cells (arrow head) as in normal control group. (Avidin–biotin complex system – bar = 50 lm).
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endothelial cells. Moderate to strong positivity was counted as
a positive reaction. Sections for control reaction gave a nega-
tive VEGF stain by omitting 1ry antibody. Normal control li-
ver sections showed a small number of VEGF positivity eitherin hepatocytes or endothelial cells (Fig. 14). In group IV after
2-NP injection, examined sections revealed a slight increase in
the number of VEGF positivity after 4 weeks, increased VEGF
positivity after 8 weeks and massive positivity after 14 weeks
referring to the elevation in angiogenesis in the liver tissue
Table 2 Comparison between VEGF positive cells in the ﬁve studied groups after 4, 8, and 14 weeks.
Group Range Mean ± SD p Value
p1 p2 p3 p4
Group I(n= 10) 4 weeks 1.0–6.0 3.40–1.65
8 weeks 1.0–6.0 3.50 ± 1.58
14 weeks 2.0–5.0 3.10 ± 0.99
Group II (n= 10) 4 weeks 1.0–6.0 2.90 ± 1.37 NS
8 weeks 1.0–5.0 2.70 ± 1.16 NS
14 weeks 1.0–4.0 2.90 ± 0.99 NS
Group III (n= 10) 4 weeks 1.0–5.0 2.50 ± 1.27 NS NS
8 weeks 1.0–5.0 2.40 ± 1.35 NS NS
14 weeks 1.0–4.0 2.30 ± 1.16 NS NS
Group IV (n= 10) 4 weeks 5.0–11.0 8.60 ± 2.01 <0.001*** <0.001*** <0.001***
8 weeks 9.0–20.0 13.60 ± 4.30 <0.001*** <0.001*** <0.001***
14 weeks 17.0–29.0 21.90 ± 4.09 <0.001*** <0.001*** <0.001***
Group V (n= 10) 4 weeks 3.0–12.0 7.20 ± 3.08 0.004** 0.002** 0.002** N S
8 weeks 3.0–11.0 7.60 ± 3.06 0.006** 0.002** 0.002** 0.005**
14 weeks 1.0–6.0 3.50 ± 1.58 NS NS NS <0.001***
p1: p Value for Mann Whitney test between group I and other groups.
p2: p Value for Mann Whitney test between group II with group III, IV and V.
p3: p Value for Mann Whitney test between group III with group IV and V.
p4: p Value for Mann Whitney test between group IV and V.
NS: not signiﬁcant at p> 0.05.
*Statistically signiﬁcant at p 6 0.05.
** Statistically signiﬁcant at p 6 0.01.
*** Statistically signiﬁcant at p 6 0.001.
Figure 16 Immunohistochemical staining of VEGF in mouse liver section post (Mel + 2-NP) treatment (Avidin biotin complex system
– bar = 50 lm) showing: (a) a decrease in number of positive VEGF reaction (arrow head) after 4 weeks. Note positivity in the sinusoids
(›). (b) Continuous decrease in number of positive VEGF reaction (›) after 8 weeks. (c) Obvious decrease in number of positive VEGF
reaction (›) after 14 weeks.
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Graph 2 A bar graph showing the mean number of VEGF
positive cells in the ﬁve studied groups after 4, 8, and 14 weeks.
218 A.A. Abdel-Mawla et al.(Fig. 15a, b and c). In group V after (Mel + 2-NP) injection,
examined sections showed a decrease in VEGF positivity after
4 weeks, a continuous decreased VEGF positivity after 8 weeks
either in hepatocytes or in the sinusoidal lining cells and a dra-
matic decrease in VEGF positivity as compared with group IV
at the same intervals (Fig. 16a, b and c).
The immunohistochemical changes in VEGF positivity
between different groups or inside one group at different inter-
vals were summarized and illustrated in Table 2 and Graph 2.
Table 2 demonstrates that the number of VEGF positivity
cells was signiﬁcantly higher (p 6 0.001) in group IV than in
group I, group II, and group III after 4 and 8 weeks. There
was no signiﬁcant difference (p> 0.05) in group IV from
group V after 4 weeks and a signiﬁcant difference (p 6 0.01)
from group V after 8 weeks. Group V was signiﬁcantly higher
(p 6 0.01) than group I, group II and group III after 4 weeks.
After 14 weeks, the number of VEGF positivity was signiﬁ-
cantly higher (p 6 0.001) in group IV than in group I, group
II, group III and group V. There was no signiﬁcant difference
(p> 0.05) between group I, group II, group III and group V.
Discussion
Hepatocarcinogenesis was a long-term, multistage process with
the involvement of multiple risk factors (Chen and Chen, 2002).
Chemical exposure is one of these important risk factors caus-
ing HCC (Hussain et al., 2007). 2-nitropropane (2-NP) as a
hepatocarcinogen was denitriﬁed to nitrite and acetone by liver
microsomes (Sohn and Fiala, 2000). This metabolic activation
was responsible for the hepatotoxicity of 2-NP due the resulting
reactive oxygen species which led to cellular damage (Borges
et al., 2006). In the present study, mice hepatocellular carci-
noma had been induced by 2-nitropropane which was a widely
used industrial solvent (Sakano et al., 2001). 2-NP showed var-
iable histopathological changes with respect to the period of
exposure. There was acute and chronic inﬁltration of inﬂamma-
tory cells with a loss of cellular architecture, in addition to the
presence of necrotic cells in the centrilobular region. Necrosis
varied from spotty necrosis to massive giant malignant necrotic
cells. Inﬁltration of inﬂammatory lymphocytes ranged from low
to heavy inﬁltration with cholestasis. Disturbance of hepatocytestructure included swelling, vacuolization of liver cells and cyto-
plasmic degeneration. Prominent apoptosis and congestion of
the central vein were also noticed. Our results were in accor-
dance with many authors who studied the hepatotoxicity of 2-
NP and reported through their researches different alterations
in the liver tissue (Bataller et al., 2003; Borges et al., 2006; Ibra-
him et al., 2010 andWilhelm et al.,2010, 2011). These alterations
reﬂected the direct effect of 2-NP on the liver tissue where it re-
leased dangerous ROS and RNS which were in turn one of the
HCC causes. This was in accordance with Marx (2004) and Sei-
tz and Stickel (2006) who reported that the commonmechanism
for hepatocarcinogenesis was chronic inﬂammation associated
with severe oxidative stress.
Another interesting observation in the present study was
the histological picture which showed incredible changes with
time progression. Giant hyperchromatic nuclei were observed
associated with massive necrosis and dilated central vein
reﬂecting a ﬁgure of well differentiated hepatocellular carci-
noma till reaching a macroscopic multinoduled liver on top
of necrosis that was seen by the naked eye. Microscopically,
these nodules showed proliferating streaks and cords of malig-
nant hepatocytes. This unique result overcame the previous
universal acceptable large body of evidences considering 2-
NP carcinogenicity, especially in mice (Cabelof et al., 2002
and Wilhelm et al., 2009). This revealed the potent prolifertat-
ing role of 2-NP and its carcinogenicity in mice. The carcino-
genicity of 2-NP in mice could be due to its dangerous ROS
and RNS which probably enhanced the ﬁnal irreversible stage
of carcinogenicity. The difference between our ﬁndings and the
previous studies could be attributed to either endogenous (like
strain, species) or exogenous (like dose, rate of administration
and duration) factors affecting response.
Mice, that received melatonin only in the present study,
showed more or less normal liver tissue, which was accompa-
nied with well deﬁned Kupffer cells to overcome the few necro-
tic cells. By receiving olive oil only, the liver tissue, generally,
was more or less like normal but diffused steatosis was noticed,
especially at the 6th week where there was macrosteatosis. This
might be due to an overdose of injected oil.
During our study, mice that received carcinogen showed a
decreased number of Kupffer cells compared to the mice that
received (Mel + 2-NP) which showed well deﬁned noticeable
number of Kupffer cells. This reﬂected the critical role of
Kupffer cells in the host defense mechanism.
It was greatly found that melatonin was effective in reduc-
ing cancer development. Melatonin seemed to be protective
against several cancers (Sanchez-Barcelo et al., 2003) such as
metastatic renal cell carcinoma (RCC), hepatocellular carci-
noma, and brain metastasis which had been shown to be
responsive to melatonin in different settings (Vijayalaxmi
et al., 2002).
Sener et al. (2005) and Kurcer et al. (2007) demonstrated
that animals treated with melatonin typically presented with
reduced hepatocellular necrosis. In that context , Li et al.
(2008) and Jung et al. (2009) reported that melatonin sup-
pressed the formation of pro-inﬂammatory cytokines such as
tumor necrosis factor- (TNF-), interleukin (IL)-1. In addition,
Gonza´lez-Puga et al. (2007) and Shiu (2007) demonstrated that
the induction of cell death by melatonin in cancer cells had
been described in melanoma, neuroblastoma, prostate cancer,
breast cancer and colon cancer cells alone or in combination
with other compounds.
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strated that treatment with melatonin 30 min prior 2-NP injec-
tion showed minimal inﬂammation with minimal necrosis at
the 4th and 8th week. By the 14th week, there was a high rate
of different apoptotic forms. These results illustrated the role
of melatonin in ameliorating untoward histopathological
changes induced by 2-NP.
As for catalase, it was one of the most efﬁcient enzymes
found in the peroxisomes (Ekanayake et al., 2008). 2-NP which
was known to be an excellent acute model to induce oxidative
damage (Borges et al., 2005, 2006) and catalase which is a
parameter of oxidative stress (Wilhelm et al., 2011) were dem-
onstrated in our present study. In the present study, the con-
trol groups (II and III) showed marked catalase reaction like
normal (group I), while group IV which received 2-NP showed
a gradual decrease in catalase reaction beginning from marked
activity till reaching moderate reaction at both the 6th and 8th
week. Catalase reaction continued to decrease till it reached a
very weak reaction at the 14th week. These results reﬂected the
oxidative stress induced by 2-NP and its prooxidant effect on
the cell. This oxidative effect of 2-NP might be due to the
NO radicals which resulted during its metabolism.
Our results showed that the treatment of mice with melato-
nin encouraged catalase activity, where catalase showed a
marked reaction like the normal group I till the 4th week of
treatment, and then decreased to be moderate across 8 weeks.
This weakness might be due to the effect of injected 2-NP.
Across the progression of treatment with (Mel + 2-NP),
catalase reaction showed continual increase. We, like others
(Borges et al., 2006), attributed the reversal of catalase activity
to normal after treatment with melatonin to the antioxidant
activity of melatonin in scavenging/detoxifying the endoge-
nous metabolic peroxides generated after liver injury due to
2-NP injection. The present ﬁndings were coincident with Bor-
ges et al. (2006) who demonstrated that 2-NP inhibited cata-
lase activity and diphenyl diselenide were able to restore the
enzyme activity suggesting that 2-NP could promote lipid per-
oxidation by directly inhibiting catalase activity.
Melatonin partially or totally prevented tissue damages due
to free radicals induced by many carcinogens. These protective
actions were believed to stem from melatonin’s direct free rad-
ical scavenging and indirect antioxidant activities (Gultekin
and Hicyilmaz, 2007). Mechanisms responsible for the beneﬁ-
cial effects of melatonin and/or its metabolites included a re-
duced electron leakage and generation of ROS, protection of
macromolecules against oxidative stress and increased activity
of antioxidant enzymes (Hardeland et al., 2009 and Korkmaz
et al., 2009).
Akcay et al. (2005) demonstrated that, treatment with mel-
atonin 15 min after kainic acid injection kept malondialde-
hyde, catalase and super oxide dismutase activities at the
normal levels.
In contrast, Wilhelm et al. (2010) demonstrated that lipid
peroxidation levels were induced by 2-NP while the decrease
in catalase activity was caused by carbon tetrachloride
(CCl4). Catalase activity remained unaltered in the liver of rats
exposed to 2-NP. This contradiction could be due to the dose
and animal differences.
Concerning vascular endothelial growth factor (VEGF)
and proliferating cell nuclear antigen (PCNA), it was univer-
sally accepted that biomarkers could be measured and evalu-
ated as indicators of normal biological or pathologicalprocesses or as pharmacological response to a therapeutic
intervention. Molecular indicators for the HCC malignancy
phenotype included alterations in DNA ploidy, nuclear mor-
phology, and the expression levels of proteins involved in cel-
lular proliferation such as tumor suppressors and cell cycle
regulators, apoptotic factors, telomerase activity, adhesion
molecules, extracellular matrix proteinases, and angiogenic
factors (Armengol et al., 2003 and Moon et al., 2003).
Our study demonstrated PCNA and VEGF immunohisto-
chemically as potential molecular biomarkers. These immuno-
histochemical investigations were carried out in order to
improve our understanding of histopatholiogical changes.
It was suggested that cancer often correlated with elevated
levels of PCNA whose levels were used as a prognostic marker
in some cases (Czyzewska et al., 2004).
Inside group IV, 2-NP injection showed a gradual increase
in PCNA reaction as time progressed where there was a signif-
icant difference (p 6 0.01) between all durations (4th, 8th and
14th weeks). The results which showed the incredible effect of
2-NP were at the 14th week .In addition, they were signiﬁ-
cantly higher (p 6 0.01) than the 4th and 8th week. Inside
group V, (Mel + 2-NP) treatment showed alternative signiﬁ-
cant results of the number of PCNA positive nuclei among
the 4th and 8th weeks. Starting from the 14th week, there
was a signiﬁcant decrease in PCNA reactivity with the 4th
week but not signiﬁcant with the 8th week.
All these results reﬂected and conﬁrmed the antiprolifera-
tive effect of melatonin (Manda et al., 2007) versus the prolif-
erative effect of 2-NP (Kohl et al., 1995). However, at the 4th
week, the slight increase in PCNA reaction of group V when
compared to group IV might be attributed to the proliferative
effect of 2-NP. This result was more or less similar to the re-
sults of Zupancˇicˇ et al. (2008) who demonstrated that melato-
nin co-treatment with cyclophosphamide signiﬁcantly
increased proliferation of urothelial cells at day 1 preventing
extensive loss of cells from the urothelium. However, they
found that, proliferation indices at days 4 and 7 after melato-
nin and cyclophosphamide co-treatment suddenly dropped
and therefore the development of hyperplasia was prevented.
Our results were in agreement with Fan et al. (2010) who
demonstrated that treatment with melatonin alone had a
dose-dependent inhibitory effect on cell proliferation. Support-
ing this idea, Garcı´a-Santos et al. (2006) showed that high con-
centrations of melatonin inhibited cell proliferation in some of
tumors via an ROS-involved pathway and with (Marti´n-Ren-
edo et al., 2008) who demonstrated that melatonin reduced the
proliferation of different cancer cell lines as a result of its abil-
ity to increase the degradation of calmoduline, which was a
key player in cell proliferation.
Another interesting investigation in this line was that of
Gu¨ndu¨z et al. (2006) who assessed the proliferative and apop-
totic processes by PCNA. They found increased proliferative
activation but no testicular progression in Syrian hamsters that
underwent pinealoctomy and were exposed to a short photope-
riod of 8 weeks. In line with that, Vesnushkin et al. (2006) re-
vealed that melatonin decreased the growth rates of tumors
in vivo both in the transplantable animal model and the animal
model induced by the administration of carcinogens.
VEGF was the most active endogenous pro-angiogenic fac-
tor and the speciﬁc endothelial cell mutagen. It was a potent
enhancer of angiogenesis and vascular permeability (Hurwitz
et al., 2004). Angiogenesis was essential in tumor growth and
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acterized by a high level of vascularization (Zachary, 2003). In
line with that, Liu et al. (2003) showed that VEGF expression
in HCC was signiﬁcantly higher than in normal liver tissue.
Melatonin’s possible inﬂuence on angiogenesis (a major mech-
anism responsible for tumor growth and dissemination) had
been addressed (Lissoni et al., 2001).
The treatment of 2-NP injection in group IV, showed a
gradual increase in VEGF positivity as time progressed, where
there was a signiﬁcant difference (p 6 0.01) between the 4th
week and each of the 8th and 14th week. Also, there was a sig-
niﬁcant difference (p 6 0.05) between the 8th and 14th week
when compared with each other. Some of the results which
showed the incredible effect of 2-NP was at the 14th week. This
signiﬁcant increase in VEGF as time progress reﬂected an in-
crease in angiogenesis which tumor need and conﬁrmed the
angiogenic role of 2-NP.
Inside group V, (Mel + 2-NP) treatment showed, gener-
ally, signiﬁcant decrease in the number of VEGF positivity,
particularly at the 14th week. Between the 4th and 8th week,
there was no signiﬁcant difference in the number of VEGF
positivity. At the 14th week obvious signiﬁcant decreases were
noticed when compared to the 4th week and the 8th week.
Our results were coincident with Wo¨lﬂer et al. (2001) who
revealed an oncostatic action of melatonin controlling tumor
growth and inhibiting cell proliferation, in addition to exerting
proapoptotic effects. In line with that, Cui et al. (2006) inves-
tigated that melatonin suppressed angiogenesis directly or indi-
rectly and pharmacologic concentrations of melatonin had a
direct anti-angiogenic effect through the inhibition of prolifer-
ation in the vascular endothelial cell. Our results supported
Blask et al. (2005), El-Sokkary et al. (2006) and Shiu (2007)
who suggested that melatonin which was an important onco-
static agent, exerted its anti-tumor effect through immuno-
modulatory, anti-proliferative and anti-oxidant pathways. In
addition, Dai et al. (2008) reported that physiologic concentra-
tions of melatonin had no obvious impact on the VEGF
expression, whereas pharmacologic concentrations of melato-
nin suppress the VEGF, mRNA and protein levels induced
by hypoxia mimetic cobalt chloride (CoCl2).References
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